Skip to main content
Erschienen in: Metabolic Brain Disease 4/2019

02.05.2019 | Original Article

Hepatocellular carcinoma up-regulated long non-coding RNA: a putative marker in multiple sclerosis

verfasst von: Arezou Sayad, Mohammad Taheri, Shahram Arsang-Jang, Mark C. Glassy, Soudeh Ghafouri-Fard

Erschienen in: Metabolic Brain Disease | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Abstract

Highly up-regulated in liver cancer (HULC) is a cancer-associated long non-coding RNA (lncRNA) which may regulate expression of other genes by working as a competing RNA for microRNAs. In the current study, we assessed transcript levels of this lncRNA in peripheral blood of multiple sclerosis (MS) patients and healthy persons to evaluate its possible role in the pathogenesis of this inflammatory disease and its diagnostic power. The results of Multilevel Bayesian showed no significant difference between cases and controls (P = 0.002, 95% confidence interval (CI) = [3.08, 13.3]). However, based on the results of Quantile regression, there was a significant difference in HULC expression between cases and controls after controlling the effects of sex and age (P = 0.002, 95% CI = [3.08, 13.3]) which shows different trends in males and females. HULC expression was inversely correlated with age of male subjects but not female subjects. HULC transcript levels had 91.1% accuracy in diagnosis of MS disease (Specificity: 80%, Sensitivity: 86.6%). The diagnostic power of HULC was higher in male subjects aged less than 50 years (AUC = 0.923, Specificity: 80%, Sensitivity: 100%). The present study shows the possibility of application of transcript levels of HULC as diagnostic marker in MS disease. However, future studies with larger sample sizes are necessary to validate our results.
Literatur
Zurück zum Zitat Hsu SH, Wang B, Kota J, Yu J, Costinean S, Kutay H, Yu L, Bai S, la Perle K, Chivukula RR, Mao H, Wei M, Clark KR, Mendell JR, Caligiuri MA, Jacob ST, Mendell JT, Ghoshal K (2012) Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J Clin Invest 122:2871–2883. https://doi.org/10.1172/jci63539 CrossRefPubMed Hsu SH, Wang B, Kota J, Yu J, Costinean S, Kutay H, Yu L, Bai S, la Perle K, Chivukula RR, Mao H, Wei M, Clark KR, Mendell JR, Caligiuri MA, Jacob ST, Mendell JT, Ghoshal K (2012) Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J Clin Invest 122:2871–2883. https://​doi.​org/​10.​1172/​jci63539 CrossRefPubMed
Zurück zum Zitat Li SP, Xu HX, Yu Y, He JD, Wang Z, Xu YJ, Wang CY, Zhang HM, Zhang RX, Zhang JJ, Yao Z, Shen ZY (2016) LncRNA HULC enhances epithelial-mesenchymal transition to promote tumorigenesis and metastasis of hepatocellular carcinoma via the miR-200a-3p/ZEB1 signaling pathway. Oncotarget 7:42431–42446. https://doi.org/10.18632/oncotarget.9883 CrossRefPubMed Li SP, Xu HX, Yu Y, He JD, Wang Z, Xu YJ, Wang CY, Zhang HM, Zhang RX, Zhang JJ, Yao Z, Shen ZY (2016) LncRNA HULC enhances epithelial-mesenchymal transition to promote tumorigenesis and metastasis of hepatocellular carcinoma via the miR-200a-3p/ZEB1 signaling pathway. Oncotarget 7:42431–42446. https://​doi.​org/​10.​18632/​oncotarget.​9883 CrossRefPubMed
Zurück zum Zitat Oldoni E et al (2017) Long non coding RNA expression profile in Peripheral Blood Mononuclear Cells from multiple sclerosis patients: potential biomarkers of disease susceptibility and progression. In: Multiple Sclerosis Journal, 2017. Sage Publications LTD 1 Olivers Yard, 55 City Road, London EC1Y 1SP, England, pp 580–581 Oldoni E et al (2017) Long non coding RNA expression profile in Peripheral Blood Mononuclear Cells from multiple sclerosis patients: potential biomarkers of disease susceptibility and progression. In: Multiple Sclerosis Journal, 2017. Sage Publications LTD 1 Olivers Yard, 55 City Road, London EC1Y 1SP, England, pp 580–581
Metadaten
Titel
Hepatocellular carcinoma up-regulated long non-coding RNA: a putative marker in multiple sclerosis
verfasst von
Arezou Sayad
Mohammad Taheri
Shahram Arsang-Jang
Mark C. Glassy
Soudeh Ghafouri-Fard
Publikationsdatum
02.05.2019
Verlag
Springer US
Erschienen in
Metabolic Brain Disease / Ausgabe 4/2019
Print ISSN: 0885-7490
Elektronische ISSN: 1573-7365
DOI
https://doi.org/10.1007/s11011-019-00418-z

Weitere Artikel der Ausgabe 4/2019

Metabolic Brain Disease 4/2019 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.